IL152738A0 - Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system - Google Patents

Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system

Info

Publication number
IL152738A0
IL152738A0 IL15273800A IL15273800A IL152738A0 IL 152738 A0 IL152738 A0 IL 152738A0 IL 15273800 A IL15273800 A IL 15273800A IL 15273800 A IL15273800 A IL 15273800A IL 152738 A0 IL152738 A0 IL 152738A0
Authority
IL
Israel
Prior art keywords
autoantibodies
nervous system
central nervous
monomers
fragments
Prior art date
Application number
IL15273800A
Other languages
English (en)
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Publication of IL152738A0 publication Critical patent/IL152738A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
IL15273800A 2000-05-10 2000-05-30 Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system IL152738A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56835100A 2000-05-10 2000-05-10
PCT/US2000/014902 WO2001085797A1 (en) 2000-05-10 2000-05-30 Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system

Publications (1)

Publication Number Publication Date
IL152738A0 true IL152738A0 (en) 2003-06-24

Family

ID=24270921

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15273800A IL152738A0 (en) 2000-05-10 2000-05-30 Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
IL152738A IL152738A (en) 2000-05-10 2002-11-10 Human IGM antibodies capable of binding to oligodendrocytes and preparations and their uses
IL212686A IL212686A (en) 2000-05-10 2011-05-04 Human IgM antibodies that bind to oligodendrocytes and their preparations and their uses

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL152738A IL152738A (en) 2000-05-10 2002-11-10 Human IGM antibodies capable of binding to oligodendrocytes and preparations and their uses
IL212686A IL212686A (en) 2000-05-10 2011-05-04 Human IgM antibodies that bind to oligodendrocytes and their preparations and their uses

Country Status (11)

Country Link
EP (3) EP2287191B1 (zh)
JP (2) JP5670608B2 (zh)
AT (1) ATE536375T1 (zh)
AU (2) AU2000261978B2 (zh)
BR (1) BR0015875A (zh)
CA (2) CA2901451C (zh)
ES (3) ES2609494T3 (zh)
HK (1) HK1154604A1 (zh)
IL (3) IL152738A0 (zh)
MX (2) MX347175B (zh)
WO (1) WO2001085797A1 (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
PT1459065E (pt) 2001-12-04 2010-10-11 Teva Pharma Processos para a medição da potência do acetato de glatirâmero
BR0307975A (pt) 2002-02-25 2005-01-11 Elan Pharm Inc Métodos para reduzir cronicamente a inflamação patológica em um paciente e para determinar a eficácia de um regime de administração crÈnica para tratar inflamação patológica em um indivìduo, composição e terapia combinada para tratamento crÈnico de inflamação patológica em um paciente e uso de um inibidor de alfa-4-integrina
SK50642005A3 (sk) * 2003-01-24 2006-02-02 Elan Pharmaceuticals, Inc. Kompozícia na liečenie demyelizačných ochorení a paralýzy podávaním remyelizačných látok
PL1648427T3 (pl) * 2003-05-16 2014-05-30 Mayo Found Medical Education & Res Leczenie zaburzeń demielinizacyjnych niskimi dawkami przeciwciała IgM
DK1626992T3 (da) * 2003-05-23 2010-09-20 Crucell Holland Bv Produktion af rekombinant IgM i PER.C6-celler
US7501119B2 (en) 2004-06-30 2009-03-10 Mayo Foundation For Medical Education And Research Methods and molecules for modulating an immune response
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
CA2680564C (en) 2007-03-12 2018-05-01 Esbatech Ag Sequence based engineering and optimization of single chain antibodies
WO2009000099A2 (en) * 2007-06-25 2008-12-31 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
DK2164961T3 (en) 2007-06-25 2015-03-02 Esbatech Alcon Biomed Res Unit Sequence based forward position and optimization of single chain ​​antibodies
WO2010046876A1 (en) * 2008-10-22 2010-04-29 Universidade De Coimbra Method for the Functional identification of SVZ-derived oligodendrocytes based on selective resuponse to thrombin and utilization thereof
WO2012045324A1 (en) * 2010-10-07 2012-04-12 Mediagnost Gesellschaft Fur Forschung Und Herstellung Von Diagnostika Gmbh Method for detecting a parkinson's disease and test system
CN104725507B (zh) 2010-10-19 2018-12-21 梅奥医学教育和研究基金会 用于治疗神经疾病的人抗体及其诊断和治疗用途
EP2701723B1 (en) * 2011-04-28 2017-08-30 Mayo Foundation For Medical Education And Research Dna aptamers for promoting remyelination
KR20200126005A (ko) * 2012-02-29 2020-11-05 박스알타 인코퍼레이티드 말초 신경의 IgG 자극된 재수초화
ES2870717T3 (es) * 2012-04-17 2021-10-27 Mayo Found Medical Education & Res Anticuerpos humanos y secuencias de unión específicas del mismo para su uso en accidente cerebrovascular e isquemia y condiciones isquémicas
WO2016073963A1 (en) 2014-11-07 2016-05-12 Mayo Foundation For Medical Education And Research Treatment of neonatal hypoxia including impairments or effects thereof
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF DISEASES
RU2736070C1 (ru) * 2019-09-30 2020-11-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Тест-модель для исследования действия лекарственных препаратов, препятствующих демиелинизации, способ ее получения и применения

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
DE3167442D1 (en) 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4451570A (en) 1981-03-26 1984-05-29 The Regents Of The University Of California Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
WO1992005263A1 (en) 1990-09-25 1992-04-02 Cantab Pharmaceuticals Research Limited Viral defective vaccine produced by transcomplementing cell line
AU696336B2 (en) 1993-03-19 1998-09-10 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. HSV) as vaccine
EP0711354A1 (en) 1993-07-30 1996-05-15 University Of Medicine & Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes
CA2187818A1 (en) 1994-04-15 1995-10-26 Robert W. Overell Gene delivery fusion proteins
US5591629A (en) * 1994-04-29 1997-01-07 Mayo Foundation For Medical Education & Research Monoclonal antibodies which promote central nervous system remyelination

Also Published As

Publication number Publication date
CA2901451A1 (en) 2001-11-15
IL212686A (en) 2014-07-31
BR0015875A (pt) 2003-06-24
JP5670608B2 (ja) 2015-02-18
EP2287190A3 (en) 2011-03-23
AU2000261978B2 (en) 2006-07-06
IL212686A0 (en) 2011-07-31
ATE536375T1 (de) 2011-12-15
EP2287190A2 (en) 2011-02-23
EP1294770B1 (en) 2011-12-07
CA2409515A1 (en) 2001-11-15
EP2287191B1 (en) 2016-10-12
WO2001085797A1 (en) 2001-11-15
ES2376725T3 (es) 2012-03-16
CA2901451C (en) 2020-04-07
HK1154604A1 (zh) 2012-04-27
CA2409515C (en) 2015-11-24
ES2609494T3 (es) 2017-04-20
AU6197800A (en) 2001-11-20
ES2531552T3 (es) 2015-03-17
EP2287191A3 (en) 2011-03-30
JP2013059318A (ja) 2013-04-04
IL152738A (en) 2011-06-30
MX347175B (es) 2017-04-17
MXPA02011163A (es) 2004-08-19
EP2287191A2 (en) 2011-02-23
JP2004516807A (ja) 2004-06-10
EP1294770A1 (en) 2003-03-26
JP5795753B2 (ja) 2015-10-14
EP2287190B1 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
HK1154604A1 (zh) 具有誘導再髓鞘化能力的人 抗體及其特別是用於中樞神經系統診斷和治療用途
KR100483494B1 (ko) 감마 인터페론에 대한 인간화 항체
Losman et al. Monoclonal autoantibodies to subnucleosomes from a MRL/Mp (-)+/+ mouse. Oligoclonality of the antibody response and recognition of a determinant composed of histones H2A, H2B, and DNA.
RU2207878C2 (ru) "очеловеченные" антитела против gp39 человека, композиции, содержащие эти антитела, и их терапевтическое использование
JP4252061B2 (ja) 選択的ＩＦＮ−γ経路インヒビターとしてのヒト抗ＩＦＮ−γ中和抗体
JP4482054B2 (ja) 細胞内の物質移送のための抗体から誘導されたベクター
ES2346517T3 (es) Anticuerpo modificado anti-tnf alfa.
JP6591964B2 (ja) Ｉｃｏｓｌへの治療上の標的特異的ｖｎａｒドメインの単離
JP5758073B2 (ja) 炎症性疾患の処置のためのｃｘｃｌ１３アンタゴニストおよびその使用
Luger et al. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation
Tian et al. Three TNFR-binding domains of PGRN act independently in inhibition of TNFα binding and activity
EA010350B1 (ru) Антитела против cd3 и способы их применения
JP6974874B2 (ja) ヒトｐｄ−ｌ１タンパク質に高親和性を有するペプチド及びその使用
JP2019500012A (ja) トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法
JPH04211392A (ja) モノクローナル抗体、抗体特性を有する蛋白質、ハイブリドーマ細胞系及びモノクローナル抗体の作製法
WO2023009028A1 (ru) Однодоменное антитело и его модификации, специфически связывающиеся с rbd s белка вируса sars-cov-2
CN111448208A (zh) 用于治疗和/或预防异位性皮肤炎的il-31肽免疫原及其剂型
EA200501131A1 (ru) Парентеральные композиции пептидов для лечения системной красной волчанки
JP2009524428A5 (zh)
KR20230096959A (ko) Il-10을 포함하는 이중 시토카인 융합 단백질
WO2010132872A1 (en) Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
WO1996021020A3 (en) Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
CA2267197A1 (en) Isolation and use of motoneuronotrophic factors
ES2145061T3 (es) Diagnostico y terapia a base de peptidos para el tratamiento de las espondiloartropatias.
WO2019034883A1 (en) THERAPY AND DIAGNOSIS